



Winter Conference 2023, 5-6 December 2023, Diet and lifestyle strategies for prevention and management of multimorbidity

The association between selenium status and cognitive decline in very old adults: The Newcastle 85+ Study

G. Perri^{1,2,9}, J. C Mathers^{1,2}, C. Martin-Ruiz³, C. Parker³, K. Demircan⁴, T. S. Chillon⁴, L. Schomburg⁴, L. Robinson¹, E. J Stevenson^{1,9}, G. Terrera^{5,9}, F. F Sniehotta⁶, C. Ritchie⁵, A. Adamson^{1,9}, A. Burns^{7,9}, A.M Minihane^{8,9}, O. Shannon¹ and T.R Hill^{1,2,9}

¹Human Nutrition and Exercise Research Centre, Centre for Healthier Lives, Population Health Sciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK

²MRC-Versus Arthritis Centre for Integrated Research into Musculoskeletal Ageing (CIMA), Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK

³BioScreening Core Facility, Campus for Ageing and Vitality, Newcastle University, Newcastle upon Tyne, UK

⁴Institute for Experimental Endocrinology, Charité-Universitätsmedizin Berlin, Berlin, Germany

⁵Edinburgh Dementia Prevention, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK

⁶Population Health Science Institute, Faculty of Medical Sciences, Baddiley-Clark Building Newcastle University, Newcastle upon Tyne, UK

⁷Division of Neuroscience and Experimental Psychology, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK

⁸Nutrition and Preventive Medicine, Norwich Medical School, University of East Anglia, Norwich, UK

⁹MRC, NuBrain: UK Consortium for Optimal Nutrition for Healthy Brain Ageing, Newcastle University, Newcastle upon Tyne, UK

The trace element selenium is known to protect against oxidative damage which is known to contribute to cognitive impairment with ageing^(1,2). The aim of this study was to explore the association between selenium status (serum selenium and selenoprotein P (SELENOP)) and global cognitive performance at baseline and after 5 years in 85-year-olds living in the Northeast of England.

Serum selenium and SELENOP concentrations were measured at baseline by total reflection X-ray fluorescence (TXRF) and enzyme-linked immunosorbent assay (ELISA), respectively, in 757 participants from the Newcastle 85+ study. Global cognitive performance was assessed using the Standardized Mini-Mental State Examination (SMMSE) where scores ≤ 25 out of 30 indicated cognitive impairment. Logistic regressions explored the associations between selenium status and global cognition at baseline. Linear mixed models explored associations between selenium status and global cognition prospectively after 5 years. Covariates included sex, body mass index, physical activity, high sensitivity C-reactive protein, alcohol intake, self-rated health, medications and smoking status.

At baseline, in fully adjusted models, there was no increase in odds of cognitive impairment with serum selenium (OR 1.004, 95% CI 0.993-1.015, $p = 0.512$) or between SELENOP (OR 1.006, 95% CI 0.881-1.149, $p = 0.930$). Likewise, over 5 years, in fully adjusted models there was no association between serum selenium and cognitive impairment ($\beta 7.20^{E-4} \pm 5.57^{E-4}$, $p = 0.197$), or between SELENOP and cognitive impairment ($\beta 3.50^{E-3} \pm 6.85^{E-3}$, $p = 0.610$).

In this UK cohort of very old adults, serum selenium or SELENOP was not associated with cognitive impairment at baseline and 5 years. This was an unexpected finding despite SELENOP's key role in the brain and the observed associations in other studies. Further research is needed to explore the effect of selenium on global cognition in very old adults.

Acknowledgments

We thank the operational support from the North of England Commissioning Support Unit and the local general practitioners and staff in addition to the research, management and administrative teams and the study participants and their families for providing the data. We would also like to thank the research team at Charité Berlin and selenOmed GmbH, namely, Dr. Petra Seemann and Qian Sun, Julian Hackler and Sophie Jahn for support in analysing the biomarkers of selenium status. The NuBrain consortium is funded by a UK Nutrition Research Partnership (UK NRP) Collaborative Award, an initiative supported by the Medical Research Council (MRC), Biotechnology and Biological Sciences Research Council (BBSRC) and the National Institute for Health Research (NIHR). The project reference is: MR/T001852/1.

References

1. Baierle M, Nascimento S, Moro AM, Brucker N *et al.* (2015) *Oxid Med Cell Longev*, 1–12.
2. Pillai R, Uyehara-Lock J & Bellinger F (2014) *IUBMB Life* **66**, 229–239.
3. Akbaraly N, Hininger-Favier I, Carrire I *et al.* (2007) *Epidemiol* **18**, 52–58.
4. Gao S, Jin Y, Hall KS *et al.* (2007) *Am J Epidemiol* **165**, 955–965.